Evidence map›Paper›PMID 38758090›Full record

ArticleBrain : a journal of neurology2024

NMDA receptor autoantibodies primarily impair the extrasynaptic compartment.

Zoe Jamet, Camille Mergaux, Morgane Meras, Delphine Bouchet, Frédéric Villega, Jakob Kreye, Harald Prüss, Laurent Groc

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Immune-mediated excitotoxicity in brain disorders.Nature reviews. Immunology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. HBEGF/EGFR pathway activation by hUC-MSCs improves cognitive outcomes in anti-NMDAR encephalitis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Autoimmune encephalitis.Nature reviews. Disease primers · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Zoe JametInterdisciplinary Institute for Neuroscience, IINS, UMR 5297, University of Bordeaux, CNRS, F-33000 Bordeaux, France.
Camille MergauxInterdisciplinary Institute for Neuroscience, IINS, UMR 5297, University of Bordeaux, CNRS, F-33000 Bordeaux, France.
Morgane MerasInterdisciplinary Institute for Neuroscience, IINS, UMR 5297, University of Bordeaux, CNRS, F-33000 Bordeaux, France.
Delphine BouchetInterdisciplinary Institute for Neuroscience, IINS, UMR 5297, University of Bordeaux, CNRS, F-33000 Bordeaux, France.
Frédéric VillegaInterdisciplinary Institute for Neuroscience, IINS, UMR 5297, University of Bordeaux, CNRS, F-33000 Bordeaux, France.
Jakob KreyeGerman Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
Harald PrüssGerman Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
Laurent GrocInterdisciplinary Institute for Neuroscience, IINS, UMR 5297, University of Bordeaux, CNRS, F-33000 Bordeaux, France.ORCID 0000-0003-1814-8145

Funding

Académie Nationale de MédecineAgence Nationale de la Recherche EraNet Neuron Mental Disorders ProgramCentre National de la Recherche ScientifiqueEuropean Research Council Synergy #951294Fondation pour la Recherche Médicale FDT202204014778German Federal Ministry of Education and Research 16GW0279KGerman Research Council PR1274/9Helmholtz Association HIL-A03Labex Bordeaux BRAIN and GPR-IDEX Bordeaux
6 · The paper itself

Abstract

Autoantibodies directed against the N-methyl-D-aspartate receptor (NMDAR-Ab) are pathogenic immunoglobulins detected in patients suffering from NMDAR encephalitis. NMDAR-Ab alter the receptor membrane trafficking, synaptic transmission and neuronal network properties, leading to neurological and psychiatric symptoms in patients. Patients often have very little neuronal damage but rapid and massive (treatment-responsive) brain dysfunctions related to an unknown early mechanism of NMDAR-Ab. Our understanding of this early molecular cascade remains surprisingly fragmented. Here, we used a combination of single molecule-based imaging of membrane proteins to unveil the spatiotemporal action of NMDAR-Ab on live hippocampal neurons. We first demonstrate that different clones of NMDAR-Ab primarily affect extrasynaptic (and not synaptic) NMDARs. In the first minutes, NMDAR-Ab increase extrasynaptic NMDAR membrane dynamics, declustering its surface interactome. NMDAR-Ab also rapidly reshuffle all membrane proteins located in the extrasynaptic compartment. Consistent with this alteration of multiple proteins, effects of NMDAR-Ab were not mediated through the sole interaction between the NMDAR and EphB2 receptor. In the long term, NMDAR-Ab reduce the NMDAR synaptic pool by slowing down receptor membrane dynamics in a cross-linking-independent manner. Remarkably, exposing only extrasynaptic NMDARs to NMDAR-Ab was sufficient to produce their full-blown effect on synaptic receptors. Collectively, we demonstrate that NMDAR-Ab initially impair extrasynaptic proteins, then the synaptic ones. These data thus shed new and unsuspected light on the mode of action of NMDAR-Ab and, probably, our understanding of (extra)synaptopathies.

Indexed as

AutoantibodiesHippocampusNeuronsReceptors, N-Methyl-D-AspartateAnimalsAnti-N-Methyl-D-Aspartate Receptor EncephalitisCells, CulturedHumansMiceRatsReceptor, EphB2SynapsesAutoantibodiesReceptor, EphB2Receptors, N-Methyl-D-Aspartateautoantibodyencephalitisextrasynaptic NMDA receptorinteractomemembrane proteins

Identifiers

PMID38758090
PMCPMC11292910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.